enzalutamide,talazoparib
astellas,pfizer
['talapro,2', 'brca', 'talazo', 'talapro-2']
talapro-2 cohort 2 (hrrm) analysis: enza+/-talazoparib rpfs: hr=0.45 (0.33-0.61) rpfs in brca1/2: hr=0.20 (0.11-0.36). no benefit in other gene clusters (atm, cdk12, palb2) os (24% maturity): hr=0.69 (0.46-1.03) gr3+ aes: 66% vs 37% (anemia: 40% vs 16%) #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧